# A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

> **NCT00116909** · PHASE2 · COMPLETED · sponsor: **OSI Pharmaceuticals** · enrollment: 85 (—)

## Conditions studied

- Locally Recurrent or Metastatic Cancer of the Head and Neck
- Must Have Failed First-Line Therapy

## Interventions

- **DRUG:** OSI 7904L

## Key facts

- **NCT ID:** NCT00116909
- **Lead sponsor:** OSI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 85 (—)
- **Last updated:** 2007-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116909, "A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT00116909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*